Industry Supported Symposium Across the Spectrum: An Update on Bipolar Disorder Supported by Sunovion
Registration Options
Activity Date: 04/20/2021
Registration is not configured for this course.
Session Time and Location
The live session is complete.
Target Audience
This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
Session Summary
There have been tremendous advances recently in the options available for treating bipolar disorder. In this compelling symposium, we will explore some of those advances and strategies for implementing them into clinical practice. The latest evidence-based diagnostic guidelines and treatments for bipolar depression will be deliberated and investigated. Novel agents and notable achievements in the treatment of disorders across the bipolar spectrum with potential applications from depression with mixed features to psychotic mania will also be discussed.
Faculty Information
Roger S. McIntyre, MD, FRCPC Stephen M. Stahl, MD, PhD, DSc (Hon.)
Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto
Toronto, ON, Canada
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018 and 2019 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr McIntyre is also the President and CEO of Champignon.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre the lead author for the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre has published more than 600 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Grant/Research: CIHR/GACD/National Natural Science Foundation of China, Stanley Medical Research Institute
Clinical Professor, Department of Psychiatry and Neuroscience
University of California
Riverside School of Medicin
Riverside, CA
Adjunct Professor
Department of Psychiatry, University of California
San Diego School of Medicine
La Jolla, CA
Honorary Visiting Senior Fellow
University of Cambridge
Cambridge, UK
Director of Psychopharmacology Services
California Department of State Hospitals
Sacramento, CA
Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the honors program in Medical Education and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry.
Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles, the Institute of Psychiatry London, the Institute of Neurology London, and, currently, at the University of California at San Diego. Dr. Stahl was also Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet and teaching how to teach.
Dr. Stahl has conducted numerous research projects during his career awarded by the National Institute of Mental Health, by the Veterans Administration and by the pharmaceutical industry. Author of over 400 articles and chapters, and more than 1200 scientific presentations and abstracts, Dr. Stahl is an internationally recognized clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited three books and written more than a dozen others, including the best-selling textbook, Stahl’s Essential Psychopharmacology, now in its third edition and the best selling clinical manual, Essential Psychopharmacology Prescriber’s Guide, also in its third edition.
Lectures, courses and preceptorships based upon his textbooks have taken him to dozens of countries on 6 continents to speak to tens of thousands of physicians, mental health professionals and students at all levels. His lectures and scientific presentations have been distributed as more than a million CD-ROMs, internet educational programs, videotapes, audiotapes and programmed home study texts for continuing medical education to hundreds of thousands of professionals in many different languages. His courses and award-winning multimedia teaching materials are used by psychopharmacology teachers and students throughout the world. Dr. Stahl also writes didactic features for mental health professionals in numerous journals.
Dr. Stahl serves as a fellow of the ACNP (American College of Neuropsychopharmacology) and of the CINP, where he was formerly vice president. He serves as associate editor of Acta Psychiatrica Scandinavica, is former clinical field editor for the International Journal of Neuropsychopharmacology and is on numerous editorial boards of other leading journals He also serves on numerous medical and scientific advisory boards for the pharmaceutical industry, for the biotechnology and medical information industry, and for various nonprofit and public service organizations, including appointment by the State of California as current Chair of the Medi-Cal Oversight Board for Medicines (Drug Utilization Review Board).
His educational research programs are monitoring changes in diagnosing and prescribing behaviors as outcomes from various educational interventions for programs organized by the Neuroscience Education Institute, which he chairs. He also has an active clinical practice specializing in psychopharmacologic treatment of resistant cases.
He has been named recipient of the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology, and also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the American Psychiatric Association/San Diego Psychiatric Society Education Award and has been cited as both one of "America’s Top Psychiatrists" and one of the "Best Doctors in America."
Strategies to Improve Patient Outcomes in Bipolar Depression
Speaker: Roger McIntyre, MD
Learning Objectives:
Improve recognition and diagnosis of bipolar depression
Optimize treatment of depression in the context of bipolar spectrum disorders
Treatment of Bipolar Spectrum Disorders: A Look Towards the Future
Speakers: Stephen M. Stahl, MD
Learning Objectives:
Contemplate recently published research that may influence the future of mental health care
Prepare to implement novel treatment strategies as they become available
Continuing Education Credit and Disclosures
Activity Date: 04/20/2021 ACPE Contact Hours: 1.5 ACPE Number: 0284-9999-21-050-L01-P (Knowledge) Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
Grant Support
This activity is supported by an educational grant from Sunovion.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.